Apollon Wealth Management LLC Boosts Stock Position in Danaher Co. (NYSE:DHR)

Apollon Wealth Management LLC grew its stake in shares of Danaher Co. (NYSE:DHR) by 2.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 21,643 shares of the conglomerate’s stock after acquiring an additional 420 shares during the period. Apollon Wealth Management LLC’s holdings in Danaher were worth $5,407,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Rakuten Securities Inc. purchased a new stake in shares of Danaher in the fourth quarter worth $36,000. Roman Butler Fullerton & Co. increased its stake in Danaher by 4.5% in the fourth quarter. Roman Butler Fullerton & Co. now owns 1,240 shares of the conglomerate’s stock valued at $289,000 after acquiring an additional 53 shares during the last quarter. Ninety One UK Ltd increased its stake in Danaher by 10.0% in the fourth quarter. Ninety One UK Ltd now owns 119,794 shares of the conglomerate’s stock valued at $27,713,000 after acquiring an additional 10,930 shares during the last quarter. Lafayette Investments Inc. increased its stake in Danaher by 5.6% in the fourth quarter. Lafayette Investments Inc. now owns 7,957 shares of the conglomerate’s stock valued at $1,841,000 after acquiring an additional 425 shares during the last quarter. Finally, HTLF Bank bought a new position in Danaher in the fourth quarter valued at $580,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Insiders Place Their Bets

In other Danaher news, CFO Matthew Mcgrew sold 16,172 shares of Danaher stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $279.84, for a total value of $4,525,572.48. Following the completion of the sale, the chief financial officer now owns 29,407 shares of the company’s stock, valued at approximately $8,229,254.88. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, CFO Matthew Mcgrew sold 16,172 shares of the business’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the completion of the sale, the chief financial officer now owns 29,407 shares of the company’s stock, valued at approximately $8,229,254.88. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Rainer Blair sold 9,007 shares of the business’s stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the sale, the chief executive officer now directly owns 97,983 shares of the company’s stock, valued at approximately $27,435,240. The disclosure for this sale can be found here. In the last quarter, insiders sold 38,707 shares of company stock valued at $10,786,944. Company insiders own 11.10% of the company’s stock.

Danaher Stock Up 0.7 %

NYSE DHR traded up $1.95 during mid-day trading on Monday, reaching $271.27. The stock had a trading volume of 1,597,552 shares, compared to its average volume of 2,854,789. Danaher Co. has a 1 year low of $182.09 and a 1 year high of $281.70. The stock has a market cap of $200.93 billion, a PE ratio of 45.65, a price-to-earnings-growth ratio of 4.62 and a beta of 0.83. The company has a fifty day moving average price of $257.69 and a 200 day moving average price of $253.60. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The company had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.59 billion. During the same period in the previous year, the business earned $2.05 EPS. The firm’s revenue for the quarter was down 2.9% on a year-over-year basis. On average, research analysts expect that Danaher Co. will post 7.59 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms recently commented on DHR. Bank of America increased their target price on Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a research note on Wednesday, July 24th. Robert W. Baird raised their price objective on Danaher from $271.00 to $278.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th. Citigroup raised their price objective on Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. Barclays raised their price objective on Danaher from $270.00 to $285.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 24th. Finally, SVB Leerink raised their price objective on Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th. Six investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $276.88.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.